Association of lysyl oxidase expression with clinicopathological features in colorectal adenocarcinomas
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Lysyl oxidase (LOX) is linked to colorectal cancer (CRC) progression and metastasis. High LOX expression in tumor cells correlates with worse survival, suggesting LOX as a potential therapeutic target.
Area Of Science
- Oncology
- Cancer Biology
- Biochemistry
Background
- Colorectal adenocarcinoma (CRC) is a major cause of cancer mortality globally.
- The tumor microenvironment (TME), including fibroblasts and enzymes like lysyl oxidase (LOX), drives CRC progression.
- LOX facilitates extracellular matrix remodeling and promotes metastasis via epithelial-mesenchymal transition (EMT).
Purpose Of The Study
- To investigate the expression of LOX in tumor cells and stroma of CRC patients.
- To correlate LOX expression with clinicopathological features and patient survival.
Main Methods
- Immunohistochemical staining of LOX proteins on colorectal tumor tissue microarrays.
- Quantification of LOX expression in tumor cells and stromal compartments.
- Statistical analysis of LOX expression and clinicopathological parameters.
Main Results
- A positive correlation was found between stromal and epithelial LOX expression.
- High LOX expression in tumor cells was significantly associated with poorer progression-free survival (PFS).
- Low stromal LOX expression correlated with reduced tumor budding.
Conclusions
- LOX expression in both tumor cells and stroma is linked to CRC progression, EMT, and metastasis.
- LOX expression patterns may improve prognostic assessment in CRC.
- Further studies are needed to validate these findings and explore LOX as a therapeutic target.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.